Thus, the ability of Nutlin-3 to activate the p53 pathway in NOTCH1 mutated B-CLL cells is noteworthy since suggests that non-genotoxic activators of p53 might be therapeutically active also in NOTCH1 mutated B-CLL patients. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.